RxDoctor Payments Data

Joseph Mazziotta, MD

Family Medicine · Tallahassee, FLNPI 1952375974

Payments from drug & device makers

$109,095in general payments, 2019–2025

Across 509 payments — averaging $214.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$102K
  • Smith+Nephew$971
  • AstraZeneca$932
  • AbbVie$734
  • Viiv Healthcare Company$639
  • Pfizer$529
  • plus $4K from 48 others

What the payments were for

  • Consulting fees$22,17520%
  • Speaking & faculty fees$70,36464%
  • Travel & lodging$5,1965%
  • Food & beverage$11,30010%
  • Education$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,095 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$58,957
Medicare patients
181
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TivicayDolutegravir Sodium32$86,894
TriumeqAbacavir/Dolutegravir/Lamivudi25$84,330
BiktarvyBictegrav/Emtricit/Tenofov Ala21$82,400
DescovyEmtricitabine/Tenofov Alafenam27$73,793
EliquisApixaban21$14,267
Janumet XrSitagliptin Phos/Metformin Hcl21$11,866
JanuviaSitagliptin Phosphate12$5,448
Celecoxib40$1,597
Atorvastatin Calcium80$1,129
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,126
Metronidazole40$915
Memantine Hcl22$751
Levothyroxine Sodium45$587
Lisinopril57$580
Amlodipine-ValsartanAmlodipine Besylate/Valsartan13$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Triumeq$639$171,22457 claims
MerckJanumet Xr, Januvia$383$17,31433 claims
PfizerEliquis$529$14,26721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →